Sexual dysfunction worsens both the general and specific quality of life of women with irritable bowel syndrome. A cross-sectional study
BMC Women's Health volume 23, Article number: 134 (2023)
Irritable bowel syndrome (IBS) and sexual dysfunction (SxD) lowers quality of life (QOL) separately, but the effect of their overlap in unselected populations has not been studied.
To evaluate the QOL of IBS women with and without SxD and compare it with controls.
In this cross-sectional assessment, we studied 51 IBS women (Rome IV criteria) and 54 controls. SxD was determined using the female sexual function index questionnaire. QOL was evaluated by the Short Form 36 (SF-36) and IBS-QOL questionnaires.
SxD prevalence was similar between IBS women (39.22%) and controls (38.89%). Compared with other groups, IBS patients with SxD showed lower scores in all domains as well as in the physical, mental summaries of the SF-36 and almost all domains (except for body image, food avoidance, and social reaction compared with IBS patients without SxD) and the total score of IBS-QOL.
These findings show that SxD worsens both general and specific QOL of women with IBS. The consideration of SxD in patients with IBS will allow us to make a more effective diagnostic and therapeutic approach. Clinical trial registry in Mexico City General Hospital: DI/19/107/03/080. Clinical trials registration: NCT04716738.
Although the use of different diagnostic criteria may prevent a complete understanding of its exact frequency, irritable bowel syndrome (IBS), a disorder of the brain-gut interaction,  affects between 3.8% (Rome IV criteria) and 9.2% (Rome III criteria) of the general population  and its frequency is almost two-fold (1.7 times)  increased in women compared with men. Only 67.7% of those affected seek information from their doctors,  but IBS still represents between 25% and 50% of gastroenterological consultations in the United States . Regardless of the high prevalence of IBS reported in Mexico (up to 35.5%), . its clinical presentation is similar to that observed worldwide.
IBS patients have more physical and psychological comorbidities, including sexual dysfunction (SxD) . In 1987, Guthrie et al  reported that up to 83% of IBS patients might have SxD. A recent study in Poland demonstrated that up to 48% of IBS female patients referred to an outpatient clinic have SxD . SxD is positively associated with the severity of gastrointestinal symptoms . The problem is so significant that specific self-management programs for SxD in IBS patients have been developed . Despite being one of the main comorbidities in IBS patients, studies on this topic are limited , and this deficiency must be corrected with primary research. Thus, there is a need to perform studies in populations where both conditions are present as a first approach to design appropriate therapeutic strategies aimed at improving medical care .
On the other hand, quality of life (QOL), which reflects subjective well-being, is reduced in patients with IBS  and SxD . Recently, Sørensen et al  reported that SxD in IBS has been studied mostly as a secondary endpoint in QOL studies, so further studies are needed. Characterizing QOL in the unselected population suffering from both conditions would be meaningful. This study aimed to evaluate the QOL of IBS women and compare it with control populations both with and without SxD.
This cross-sectional survey was conducted according to STROBE guidelines at the Gastroenterology Service, Mexico General Hospital “Eduardo Liceaga” and the Iberoamerican University following the Declaration of Helsinki and its subsequent declaration revisions. Informed consent was obtained from all subjects before the interview. This study, which investigates the prevalence of SxD in IBS patients as well as its influence on the quality of life in the Mexican female population, is part of a broader protocol that is ongoing, has been approved by the local ethics and research committees (DI/19/107/03/080) and is registered at clinicaltrials.gov (NCT04716738).
We recruited consecutive sexually active women in the open population by opportunity sampling from March to September 2019. For study inclusion, the participants must have met the following criteria: between 18 and 50 years, provided informed consent, and agreed to answer the questionnaires. We excluded women with noncontrolled systemic disease, pregnant women, breastfeeding women, menopausal women, women taking medications regularly in the previous 3 months, and women with an established diagnosis of other sexual and/or gastrointestinal diseases. Patients who did not accept contact information, did not answer the complete questionnaires, failed to understand the instructions, and/or were unreachable after the application of questionnaires were eliminated from the study.
To avoid selection bias, we applied the questionnaires in a single interview on consecutive women, and data were entered in a spreadsheet that was not analyzed immediately. We performed the first analysis 2 months after the start of the study that the psychology students presented at the Iberoamerican University. We performed a second analysis in July that was presented at the Mexican Congress of Gastroenterology. In November 2019, we performed the last interim analysis for the Digestive Disease Week. Finally, between July and December 2020, we performed the final analysis for this article.
Irritable bowel syndrome diagnosis
We used the Rome IV criteria, which specify that abdominal pain is present for more than 6 months once a week in the last 12 and at least two of the following three characteristics are noted: (a) pain related to defecation associated with changes in the (b) frequency of defecation and/or in the (c) appearance of stool .
Using a pictorial representation of the Bristol Scale, we recorded the most frequent type of stool consistency subjectively perceived by the patient (Bristol Subjective Scale, BSS) and the percentage of time in which the patient objectively observed their different consistencies (Bristol Objective Scale, BOS). To determine the BSS score, we asked patients to select which of the drawings they perceived as the most frequent. After answering this question, we evaluated the BOS by asking the patient to provide the maximum number of recent bowel movements (they mentioned between 4 and 12) and characterize the feces according to the Bristol scale. Finally, we assigned a percentage to each type of evacuation. The following IBS subtypes were determined using the BOS as suggested by the Rome IV criteria: constipation (IBS-C), diarrhea (IBS-D), mixed (IBS-M), or undetermined (IBS-U) .
Sexual dysfunction evaluation
We used the Female Sexual Function Index (FSFI), which has been validated in the Mexican population  and is considered the gold standard of female sexual functioning of women with gastrointestinal diseases . With 19 items, the FSFI evaluates six domains: desire, excitement, lubrication, orgasm, satisfaction, and pain. A higher score indicates better function. Sexual dysfunction was noted when the total score (adding the score of each domain) was less than 26.55 .
Two instruments were used assessed the patient’s attitude toward her health status based on physical, psychological, and social aspects. We used the Short-Form 36 (SF-36) questionnaire for a general QOL evaluation based on eight domains: physical function, physical role, body pain, general health, vitality, social functioning, emotional role, and mental health. The questions were coded, summarized, and transformed to a scale from 0 (worst) to 100 (best) health statuses. Additionally, the questionnaire includes question about the change in the general health state. We also calculated physical (PCS) and mental (MCS) component summaries bases on an orthogonal approximation. This questionnaire has been validated in the Mexican  and IBS populations .
Specific QOL was assessed by the irritable bowel syndrome-quality of life (IBS-QOL) questionnaire . This questionnaire evaluates eight domains (dysphoria, interference with activity, body image, health concern, food avoidance, social reaction, sexual concern, and social relationship), and a total score (the sum of all domains) is also provided. This questionnaire has been widely used in IBS . Higher scores indicate better QOL.
Sample size and power of the study
Because there are no previous articles that address the overlapping effects of IBS and SxD on QOL using the SF-36 and IBS-QOL as main outcomes in the same population, we decided to recruit consecutive women as the first approach. In a post hoc analysis (StatMate 2 for Windows, version 2.00), we found a beta power greater than 80% (with alpha < 0.05) on the size effect of the main variables (domains and total summaries of the SF-36 and IBS-QOL questionnaires), so we conclude that the sample size was sufficient to obtain statistical validity (Additional File 1 & 2).
The main outcomes were the differences in domains, component summaries, and total scores of the SF-36 and IBS-QOL. Secondary outcomes included age, body mass index (BMI), marital status, pain related to menses, frequency of defecation per week, IBS subtype, and the Bristol Scale (subjective and objective). Statistical analysis was performed with IBM® SPSS® Statistics, version 26 (Registered for Iberoamerican University). When appropriate, data indicate the mean ± standard deviation, 95 % confidence intervals (CI), range, and/or percentages. Statistical differences were evaluated by Student’s t test for parametric data, Mann‒Whitney and chi-square tests for nonparametric data, and Fisher’s exact test with the Katz approximation for relative risk (RR). Alpha = 0.05 in these analyses. We analyzed the correlation between BSS and BOS through the Pearson test.
Of the 117 women recruited, 105 (89.7%) women were included in the study (see flowchart, Fig. 1). Age, BMI with cut points, pain related to menses, marital status of the total sample, and IBS and SxD patients are reported in Table 1. IBS women were older and more likely to be in a relationship. The weekly frequency of defecation was lower in IBS patients than in controls [9.33 ± 5.85 (7.73–10.94) vs. 13.15 ± 6.89 (11.31–14.99), respectively, p = 0.002] but similar in women with SxD versus those without SxD [11.24 ± 6.64 (9.21–13.28) vs. 11.15 ± 6.61 (9.58–12.72), respectively, p = 0.94].
Quality of life and sexual dysfunction in IBS women and controls
General and specific QOL as well as FSFI domains of IBS and SxD patients are shown in Table 2. No differences in the domains and total score of the FSFI were noted between IBS patients and controls.
General QOL (SF-36)
The IBS women in our study showed lower scores in the domains of body pain, general health, and emotional role, whereas SxD women exhibited a difference in mental health. Patients with both diseases have lower scores for physical function, social functioning, PCS, and deterioration in health compared with the previous year.
Specific QOL (IBS-QOL)
IBS women scored lower on the eight domains and the total score, whereas SxD patients scored lower on seven domains (except body image) and the total score.
Overlap of IBS and SxD
IBS patients without SxD exhibited a higher BMI than SxD women. Patients with both diseases were older than controls, reported lower PCS and MCS scores, and showed health deterioration (Table 3). The IBS-QOL total score was lower in IBS women than controls. In addition, IBS women with SxD showed the lowest score even compared with IBS patients without SxD.
Patients with IBS and SxD scored lower on the eight domains of the SF-36 (Fig. 2) and five domains (except for body image, food avoidance, and social reaction that showed no differences compared with IBS women without SxD) of the IBS-QOL (Fig. 3).
IBS subtype analysis
Twenty-four (47.06%) patients were classified as IBS-U type, 20 (39.22%) were IBS-C, and 7 (13.73%) were IBS-D. No IBS-M patients were identified. No differences (p > 0.05) in SxD prevalence were found among IBS-U (29.17%), IBS-C (45%), and IBS-D (42.86%). IBS-C patients obtained lower scores on the physical function, general health, vitality, social functioning, and mental health domains than IBS-U patients (Additional File 3).
PCS was higher in IBS-U [61.7 ± 8.47 (58.32–65.09)] than in IBS-C [50.62 ± 11.94 (45.38–55.85), p = 0.0008] but not in IBS-D [53.38 ± 9.94 (46.02–60.74), p = 0.5]. No differences in MCS (p > 0.05) were noted among IBS-U [44.82 ± 6.77 (42.12–47.53)], IBS-D [45.29 ± 5.26 (41.4–49.19)], and IBS-C [42.84 ± 7.35 (39.62–46.06)]. Worse/much worse change in health perception within one year did not differ (p > 0.05) among the IBS-U (12.5%), IBS-D (28.57%) or IBS-C (35%) groups.
Additional File 4 shows the lower specific quality of life of the eight domains in IBS-C women compared with IBS-U women. The total score was lower in IBS-C [64.89 ± 25.26 (53.82–75.96)] than in IBS-U [85.72 ± 10.41 (81.56–89.89), p = 0.0006] but not in IBS-D [67.54 ± 21.83 (51.37–83.71), p = 0.8].
Concordance, which is defined as the percentage of times in which the BSS and BOS were the same between subjects in each group, was good/excellent (higher than 80%, p > 0.3, chi square test) in the total population (84%), patients with IBS (84%) and controls (83%). Similarly, the total population (r = 0.83), IBS patients (r = 0.9) and controls (r = 0.72) showed a direct correlation (p < 0.01) between BSS and BOS.
Singleness decreased the RR of IBS by 0.772 (p = 0.01) but not for SxD (RR = 0.626, p = 0.1). BMI did not affect IBS (RR = 1.3, p = 0.3) or SxD (RR = 1.1, p = 0.7) women. Pain related to menses did not differ between the IBS versus control (47.06% vs. 37.04%, respectively; RR = 0.8, p = 0.3) or SxD positive and negative (37.84% vs. 44.12%, respectively; RR = 1.1, p = 0.6) groups. BSS types 3, 4 and 5 were protective factors associated with IBS compared with controls (62.75% vs. 87.04%, respectively; RR = 0.5543, p = 0.006).
Our study suggests that SxD worsens both the general and the specific QOL of female IBS patients. We found that approximately three out of ten women had SxD (IBS and control), which is lower than that previously reported (48%) . We believe that our study more accurately reflects the prevalence of SxD because the previous study recruited patients from an outpatient clinic, whereas we recruited patients from an open population.
IBS women were older than controls. These findings are not consistent with the literature data that show a small protective factor in individuals older than 50 years . Apart from the fact that our population was younger than 50 years, a recent review shows that this difference is maintained in Western countries but not in Taiwan, suggesting that an alternate component (such as comorbidity) is involved . Our analysis is congruent with this finding because this difference disappears when comparing patients with IBS alone and controls, suggesting that SxD occurs more frequently in older IBS patients. Although IBS patients without SxD exhibited a higher BMI compared with IBS patients with SxD, BMI was in the normal range in all groups, which is consistent with the literature .
Pain related to menses did not differ among the groups. Premenopausal women with IBS report worsening of symptoms during menstruation compared with their follicular phase . This finding is similar to that noted in healthy controls, who report abdominal pain more frequently during menses . These manifestations are believed to be caused by sexual hormonal changes. We did not compare sexual cycle phases; however, we can infer that the decrease in QOL is not associated with pain related to menses.
IBS is more common in women who have had or are currently in relationships. This is finding is consistent with a study that found that married individuals had an increased odds ratio of IBS compared with nonmarried individuals (OR = 1.19) . To our knowledge, this is the first report to describe being single as a protective factor (22.7%) for developing IBS.
Our IBS patients showed a lower weekly frequency of defecation, which is consistent with alterations in bowel movement as a diagnostic feature of IBS . Interestingly, this difference disappears in SxD women. This finding potentially indicates that the frequency of defecation does not influence SxD, a finding not reported hitherto. Consistently, no differences in FSFI questionnaire scores were noted among IBS patients, which suggests that SxD is not influenced by IBS in a nonselected population; however, lower scores have been reported for IBS outpatients . This difference may be explained by the fact that, for example, IBS-C outpatients are predisposed to report comorbidities, such as inflammatory bowel disease, more frequently to an obstetrician/gynecologist than other conditions .
A direct correlation was noted between subjective perception and objective recollection of fecal consistency, which validates its clinical use. This outcome is consistent with previously reported findings . We identified a protective factor of BSS 3, 4 and 5 (50%) for IBS, a finding not reported previously.
Comparing the general QOL of IBS and SxD women separately, these patient groups share a deterioration in physical function and PCS, suggesting a common pathophysiological characteristic that would explain the poor subjective well-being perception. These findings agree with a recent study of patients with major depressive disorder treated with antidepressant drugs in which symptom responders showed an increase in functional connectivity in the dorsal anterior cingulate cortex (dACC) relative to nonresponders with improvement in physical QOL . It has been demonstrated that SxD decreases brain activity of the dACC,  and IBS patients also show a decreased amplitude of low-frequency fluctuation in the dACC . We believe this is an interesting findings that should be assessed in future research . Lower IBS-QOL scores were noted in IBS patients, and similar scores were noted in SxD women (except for body image). This finding is consistent with those previously reported .
QOL is particularly important for IBS not only as a diagnostic or pathophysiological feature but also as a prognostic effectiveness factor. The latest clinical guidelines consider QOL and comorbidity as indicators for healthcare-seeking behavior and consequently as a diagnostic-therapeutic goal . Our study adds a supporting feature to this strategy. Because SxD significantly decreases the general and specific quality of life, we should change the objectives to treat SxD simultaneously as the main comorbidity of women with IBS to adopt an approach based on patient-centered medicine as a recent review suggests .
IBS subtype analysis shows a similar prevalence of SxD, but IBS-C patients scored lower on five domains compared with IBS-U patients. Given the small sample size, we are unable to make a definitive conclusion, but this approach will be interesting to investigate in future work.
This research is the first step to elucidate the subjective perception of well-being as a diagnostic, therapeutic and prognostic objective. The clinical implications of these results are related to health-seeking behavior  and are thus important for providing a more precise determination of disease prevalence and incidence that could alter management strategies in women with IBS and SxD simultaneously.
Our study has some limitations to consider. We did not perform an exhaustive evaluation of clinical IBS or SxD. Although the diagnosis of IBS is clinical and the Rome IV criteria are sufficient to diagnose it, the possibility that abdominal pain may be secondary to another disease is latent. If we do not make a general laboratory evaluation, we will not be certain of the presence of IBS. Similarly, SxD requires a thorough psychiatric evaluation to determine which of the possible subtypes is present. Our approach assessed individuals from an open population, so we only trusted what each person reported and used self-administered questionnaires. Another limitation is that the power of prediction in cross-sectional studies is weak; thus, the RR results only serve as an approximation that should be validated in subsequent prospective studies.
Sexual dysfunction could worsen both the general and the specific quality of life of women with irritable bowel syndrome. Further investigations of clinical and pathophysiological mechanisms are needed to elucidate the relationship between both diseases and determine whether these diseases share a common mechanism that explains this low quality of life. Considering sexual dysfunction in women with irritable bowel syndrome will allow us to provide a more effective diagnostic and therapeutic patient-centered approach.
The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.
Irritable Bowel Syndrome
Quality of Life
Short Form 36 questionnaire
Irritable Bowel Syndrome-Quality of Life questionnaire
Bristol Subjective Scale
Bristol Objective Scale
Dorsal Anterior Cingulate Cortex.
Black CJ, Ford AC. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Reviews Gastroenterol Hepatol. 2020;17:473–86.
Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:908–17.
Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, results of Rome Foundation Global Study. Gastroenterology. 2021;160:99–114e3.
Shin A, Ballou S, Camilleri M, Xu H, Lembo A. Information- and Health-care seeking behaviors in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2020;18:2840–2.
Defrees DN, Bailey J. Irritable bowel syndrome: epidemiology, pathophysiology, diagnosis, and treatment. Prim Care - Clin Office Pract. 2017;44:655–71.
Sperber AD, Dumitrascu D, Fukudo S, Gerson C, Ghoshal UC, Gwee KA, et al. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review. Gut. 2017;66:1075–82.
Shiha MG, Aziz I. Review article: physical and psychological comorbidities associated with irritable bowel syndrome. Aliment Pharmacol Ther. 2021;54:12–23.
Guthrie E, Creed F, Whorwell PJ. Severe sexual dysfunction in women with the irritable bowel syndrome: comparison with inflammatory bowel disease and duodenal ulceration. Br Med J (Clin Res Ed). 1987;295:577–8.
Sławik P, Szul M, Fuchs A, Waluga M, Krzystanek M. Could problems in the bedroom come from our intestines? A preliminary study of IBS and its impact on female sexuality. Psychiatr Danub. 2019;31(Suppl 3):561–7.
Fass R, Fullerton S, Naliboff B, Hirsh T, Mayer EA. Sexual dysfunction in patients with irritable bowel syndrome and non-ulcer dyspepsia. Digestion. 1998;59:79–85.
Eugenio MD, Jun SE, Cain KC, Jarrett ME, Heitkemper MM. Comprehensive self-management reduces the negative impact of irritable bowel syndrome symptoms on sexual functioning. Dig Dis Sci. 2012;57:1636–46.
Romano L, Granata L, Fusco F, Napolitano L, Cerbone R, Priadko K, et al. Sexual dysfunction in patients with chronic gastrointestinal and Liver Diseases: a neglected issue. Sex Med Rev. 2022;10:620–31.
Bedell A, Friedlander A. Management of sexual dysfunction in gastrointestinal Disorders. Gastroenterol Clin North Am. 2022;51:815–28.
Mönnikes H. Quality of life in patients with irritable bowel syndrome. J Clin Gastroenterol. 2011;45 SUPPL. 2:S98–101.
Nappi RE, Cucinella L, Martella S, Rossi M, Tiranini L, Martini E. Female sexual dysfunction (FSD): prevalence and impact on quality of life (QoL). Maturitas. 2016;94:87–91.
Sørensen J, Schantz Laursen B, Drewes AM, Krarup AL. The incidence of sexual dysfunction in patients with irritable bowel syndrome. Sex Med. 2019;7:371–83.
Lacy BE, Mearin F, Chang L, Chey WD, Lembo AJ, Simren M, et al. Bowel disorders Gastroenterology. 2016;150:1393–1407e5.
Carranza-Lira S, De Durazno Casillas Núñez F. Sexual dysfunction prevalence in a group of pre-and postmenopausal mexican women. Przeglad Menopauzalny. 2018;17:39–42.
Meston CM, Freihart BK, Handy AB, Kilimnik CD, Rosen RC. Scoring and interpretation of the FSFI: what can be learned from 20 years of use? J Sex Med. 2020;17:17–25.
Durán-Arenas L, Gallegos-Carrillo K, Salinas-Escudero G, Martínez-Salgado H. [Towards a mexican normative standard for measurement of the short format 36 health-related quality of life instrument]. Salud Publica Mex. 2004;46:306–15.
Remes-Troche JM, Torres-Aguilera M, Montes-Martínez V, Jiménez-García VA, Roesch-Dietlen F. Prevalence of irritable bowel syndrome in caregivers of patients with chronic diseases. Neurogastroenterol Motil. 2015;27:824–31.
Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a Meta-analysis. Clin Gastroenterol Hepatol. 2012;10:712–721e4.
Creed F. Review article: the incidence and risk factors for irritable bowel syndrome in population-based studies. Aliment Pharmacol Ther. 2019;50:507–16.
Beh KH, Chuah KH, Mahamad Rappek NA, Mahadeva S. The association of body mass index with functional dyspepsia is independent of psychological morbidity: a cross-sectional study. PLoS ONE. 2021;16:1.
Pati GK, Kar C, Narayan J, Uthansingh K, Behera M, Sahu MK et al. Irritable Bowel Syndrome and the Menstrual Cycle.Cureus. 2021;13.
Bernstein MT, Graff LA, Avery L, Palatnick C, Parnerowski K, Targownik LE. Gastrointestinal symptoms before and during menses in healthy women.BMC Womens Health. 2014;14.
Keshteli AH, Dehestani B, Daghaghzadeh H, Adibi P. Epidemiological features of irritable bowel syndrome and its subtypes among iranian adults. Ann Gastroenterol. 2015;28:253–8.
Blake MR, Raker JM, Whelan K. Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2016;44:693–703.
Fischer AS, Holt-Gosselin B, Fleming SL, Hack LM, Ball TM, Schatzberg AF, et al. Intrinsic reward circuit connectivity profiles underlying symptom and quality of life outcomes following antidepressant medication: a report from the iSPOT-D trial. Neuropsychopharmacology. 2021;46:809–19.
Poeppl TB, Langguth B, Laird AR, Eickhoff SB. Meta-analytic evidence for neural dysactivity underlying sexual dysfunction. J Sex Med. 2019;16:614–7.
Qi R, Liu C, Ke J, Xu Q, Zhong J, Wang F, et al. Intrinsic brain abnormalities in irritable bowel syndrome and effect of anxiety and depression. Brain Imaging Behav. 2016;10:1127–34.
Matisz CE, Gruber AJ. Neuroinflammatory remodeling of the anterior cingulate cortex as a key driver of mood disorders in gastrointestinal disease and disorders. Neurosci Biobehav Rev. 2021;133:104497. https://doi.org/10.1016/j.neubiorev.2021.12.020.
Vasant DH, Paine PA, Black CJ, Houghton LA, Everitt HA, Corsetti M et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome.Gut. 2021;:gutjnl-2021-324598.
Camilleri M. Diagnosis and treatment of irritable bowel syndrome: a review. JAMA - Journal of the American Medical Association. 2021;325:865–77.
Dheresa M, Worku A, Oljira L, Mengistie B, Assefa N, Berhane Y. Women’s health seeking behavior for pelvic floor disorders and its associated factors in eastern Ethiopia. Int Urogynecol J. 2020;31:1263–71.
We thank MAPI Institute for their consent to use the IBS-QOL questionnaire free of charge for this study. We also thank Dr. Livan Delgado and Javier Reyes-Mendez for his administrative support.
Open Access funding enabled and organized by Projekt DEAL.
Editing service and article-processing charge have been paid by a grant of Laboratorios Liomont, S.A. de C.V.
Ethics approval and consent to participate
This study has been approved by the Mexico General Hospital “Eduardo Liceaga” ethics and research committees (DI/19/107/03/080) and registered in Clinical trials (NCT04716738). Patient consent statement: All patients provided informed consent.
Consent for publication
We declare no conflict of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Camacho, S., Díaz, A., Pérez, P. et al. Sexual dysfunction worsens both the general and specific quality of life of women with irritable bowel syndrome. A cross-sectional study. BMC Women's Health 23, 134 (2023). https://doi.org/10.1186/s12905-023-02272-9